Direct Oral Anticoagulants (DOACs) Market to Grow with a CAGR of 7.62% through 2030

The growing demand for personalized medicine and the advancements in DOACs formulations with improved safety profiles, is expected to drive the Global Direct Oral Anticoagulants (DOACs) Market growth in the forecast period, 2026-2030

According to TechSci Research report, “Direct Oral Anticoagulants (DOACs) Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”, the Global Direct Oral Anticoagulants (DOACs) Market stood at USD 32.06 Billion in 2024 and is expected to reach USD 49.88 Billion by 2030 with a CAGR of 7.62% during the forecast period. The Global Direct Oral Anticoagulants (DOACs) Market has witnessed robust growth driven by the shift in treatment paradigms for managing thrombotic disorders. Unlike traditional therapies, DOACs offer the benefit of fixed dosing without the need for routine monitoring or dietary restrictions. These advantages make DOACs highly appealing for patients with conditions like atrial fibrillation, deep vein thrombosis, and pulmonary embolism. As cardiovascular diseases continue to rise, particularly among the aging population, the demand for effective, convenient, and safer anticoagulation therapies is expected to remain strong, contributing to the market’s expansion.

One of the primary growth drivers in the DOACs Market is the increasing shift toward non-vitamin K antagonist oral anticoagulants (NOACs) due to their improved ease of use and safety. Unlike warfarin, which requires regular blood tests and dietary restrictions, DOACs offer an enhanced therapeutic profile with lower rates of bleeding complications. The growing adoption of DOACs in both inpatient and outpatient settings is driven by their predictable pharmacodynamics, which reduce the risk of adverse events and simplify treatment protocols. This trend is further supported by the rising prevalence of atrial fibrillation, one of the most common arrhythmias, which requires long-term anticoagulation therapy for stroke prevention.

Growth opportunities in the DOACs market lie in expanding access to these drugs in emerging markets where healthcare infrastructure is evolving and the prevalence of cardiovascular diseases is rising rapidly. With rising disposable incomes, better healthcare infrastructure, and an increasing focus on chronic disease management, regions like Asia-Pacific, Latin America, and the Middle East present significant growth potential. Pharmaceutical companies can tap into these regions by introducing cost-effective generics, improving market penetration, and partnering with local healthcare providers. The increased awareness of stroke prevention and thrombosis management is also expected to drive demand for DOACs, presenting opportunities for new product launches and therapeutic advancements.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Direct Oral Anticoagulants (DOACs) Market”

The Global Direct Oral Anticoagulants (DOACs) Market is segmented into drug type, indication, end user, regional distribution, and company.

Based on the Indication, Atrial Fibrillation (AF) emerged as the fastest growing segment in the Global Direct Oral Anticoagulants (DOACs) Market during the forecast period. This is due to the rising global prevalence of AF and the increasing awareness of stroke prevention. AF is one of the most common cardiac arrhythmias, significantly elevating the risk of stroke and systemic embolism. As the aging population grows, particularly in developed nations, the incidence of AF is increasing, leading to a higher demand for effective and convenient anticoagulation therapies. DOACs have become the preferred treatment option over traditional vitamin K antagonists like warfarin due to their predictable pharmacokinetics, fewer dietary restrictions, and reduced need for frequent monitoring. The rapid adoption of DOACs in AF management is also driven by strong clinical evidence supporting their superior efficacy and safety profile compared to warfarin. Regulatory approvals for expanded indications, along with guideline recommendations favoring DOACs for stroke prevention in AF patients, have further accelerated market growth. Pharmaceutical companies continue to invest in new formulations, patient education programs, and improved access to DOACs through reimbursement policies.

Based on the Region, Asia-Pacific emerged as the fastest growing region in the Global Direct Oral Anticoagulants (DOACs) Market during the forecast period. This is during the forecast period due to the rising prevalence of cardiovascular diseases, increasing healthcare awareness, and expanding access to advanced anticoagulation therapies. The region is experiencing a significant surge in atrial fibrillation (AF), deep vein thrombosis (DVT), and pulmonary embolism (PE) cases, primarily driven by aging populations, sedentary lifestyles, and the growing burden of non-communicable diseases. As more patients are diagnosed with thromboembolic disorders, the demand for effective and convenient anticoagulation options such as DOACs continues to rise. The rapid market growth is further fueled by government initiatives to improve healthcare infrastructure, increasing healthcare expenditure, and regulatory approvals for DOACs in emerging economies like China, India, and Southeast Asian nations. The presence of both global and regional pharmaceutical companies investing in research, clinical trials, and marketing efforts has enhanced the availability and affordability of DOACs. Additionally, rising physician preference for DOACs over traditional anticoagulants due to their ease of administration and lower risk of bleeding complications has contributed to their widespread adoption. With continuous advancements in healthcare access and patient awareness programs, the Asia-Pacific region is expected to sustain its strong growth trajectory in the coming years.

Major companies operating in Global Direct Oral Anticoagulants (DOACs) Market are:

• Bayer AG
• Boehringer Ingelheim International GmbH
• Bristol Myers Squibb Company
• Pfizer Inc.
• Sanofi
• Zhejiang Huahai Pharmaceutical Co. Ltd.
• Janssen Global Services, LLC
• Aspen Pharmacare Holdings Limited
• Astellas Pharma Inc.
• Lupin Pharmaceutical, Inc.

Download Free Sample Report

Customers can also request for 10% free customization on this report

“The Global Direct Oral Anticoagulants (DOACs) Market is expanding due to the rising trend of patient-centric healthcare, where the convenience and ease of DOAC administration are highly valued. Unlike traditional anticoagulants, DOACs do not require regular monitoring or dietary restrictions, making them more attractive to patients who prefer treatments that fit into their lifestyle. The growing emphasis on improving patient adherence to treatment plans, especially in chronic conditions like atrial fibrillation and deep vein thrombosis, is pushing healthcare providers to opt for oral anticoagulants that offer ease of use. As patients increasingly demand user-friendly therapeutic options, DOACs are expected to see greater adoption, driving the market forward.,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Direct Oral Anticoagulants (DOACs) Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type (Factor Xa Inhibitors, Direct Thrombin Inhibitors), By Indication (Atrial Fibrillation (AF), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Stroke Prevention, Others), By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, Others), By Region and Competition, 2020-2030F”, has evaluated the future growth potential of Global Direct Oral Anticoagulants (DOACs) Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Direct Oral Anticoagulants (DOACs) Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com